#USA #San Diego #Alida Biosciences #RNA modifications #EpiPlex™ Tri-Mod™

Alida Biosciences Launches EpiPlex® Tri-Mod™ Service

Alida Biosciences has recently announced a significant advancement in the field of molecular biology with the introduction of its EpiPlex™ Tri-Mod™ Service. This innovative service allows for the simultaneous detection and quantification of three critical mRNA modifications: N6-methyladenosine (m6A), inosine, and pseudouridine. In an era where understanding RNA-level regulation is vital to unpacking the complexities of diseases, this service opens new doors for researchers and clinicians alike.

The EpiPlex platform is specially designed to facilitate sensitive and quantitative analysis of RNA modifications, especially from RNA-limited clinical samples. It offers a comprehensive workflow that includes EpiScout™ analysis software, empowering researchers to derive deeper insights from their data. The capability to profile multiple mRNA modifications at once is a leap beyond conventional methods.

Addressing the Challenge of Pseudouridine Detection

One of the standout features of the EpiPlex Tri-Mod™ Service is its resolution in detecting pseudouridine, which has historically been challenging to measure due to its chemical resemblance to uridine. Most existing short-read sequencing techniques require substantial RNA input, which can be difficult to obtain, especially from precious clinical samples. The innovative enzyme-driven chemistry utilized by EpiPlex Tri-Mod™ transforms pseudouridine into a readable signal with single-base resolution, all while detecting m6A and inosine in the same workflow.

Dr. Wendy Gilbert, a Professor of Molecular Biophysics and Biochemistry at Yale University, commented on this breakthrough, stating, “EpiPlex's enzyme-based labeling of pseudouridine, along with its proximity barcoding strategy, offers a level of sensitivity that surpasses traditional methods. This progress enables research into RNA modifications in lowly expressed transcripts that have historically posed challenges.”

A New Perspective on Cell State and Disease

The application of the EpiPlex Tri-Mod™ Service enhances our understanding of the epitranscriptome, a complex regulatory landscape of RNA modifications that significantly impacts cellular functions. The modifications analyzed by this service are not only abundant but also pivotal in essential cellular processes directly linked to various human diseases.

Dr. Yi-Tao Yu, Professor of Biochemistry and Biophysics at the University of Rochester Medical Center, highlighted the unique ability of the EpiPlex Tri-Mod™ Service to provide multifaceted insights. “This method allows us to explore how different RNA modifications interact with one another, a subject that has long intrigued researchers but remained elusive.” This analytical depth enables scientists to assess RNA modifications that can functionally influence each other and highlights the relevance of these modifications in identifying changes in cell state that cannot be inferred from genomic sequencing or conventional transcriptomics.

These modifications serve as real-time indicators of cellular health, revealing vital information about immune responses, metabolic stress, and oncogenic signals. This aspect is critical for translational researchers with an interest in bridging molecular biology and clinical outcomes, as the conventional toolkit has often lacked this crucial layer of information.

Dr. Gudrun Stengel, CEO of Alida Biosciences, succinctly articulated the significance of this service: “RNA modifications play a central role in how cells react to their environment. With EpiPlex Tri-Mod™, we transition from method development to facilitating large-scale studies that fuel AI-driven models and enhance our understanding of biology in both health and disease.”

As it stands, the EpiPlex Tri-Mod™ Service is now available for collaboration with academic institutions and biopharmaceutical companies. For those interested in access or collaboration opportunities, Alida Biosciences encourages inquiries at [email protected].

Alida Biosciences has positioned itself at the forefront of epitranscriptome research, developing technologies that decode this vital regulatory layer governing gene expression and cellular function. The EpiPlex™ platform is instrumental in enabling multiplexed analyses of RNA modifications, ultimately fostering a better understanding of cellular dynamics.